Related Experiment Video

Updated: Aug 8, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

[Chronic hepatitis C--patients "difficult to treat"]

Małgorzata Pawłowska1, Waldemar Halota

  • 1Katedra i Klinika Chorób Zakaźnych i Hepatologii, Collegium Medicum Uniwersytetu Mikołaja Kopernika w Toruniu. kikchzak@cm.umk.pl

Przeglad Epidemiologiczny
|June 9, 2006
PubMed

Insights

Treating difficult Hepatitis C virus (HCV) genotypes 1 and 4 requires tailored approaches. Retreatment with pegylated interferon and ribavirin shows promise for non-responders, improving sustained virologic response (SVR).

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Virology

Background:

  • Certain patient groups, including those with HCV genotypes 1 and 4, cirrhosis, specific ethnicities, immunocompromised status, or prior treatment failure, present challenges in achieving sustained virologic response (SVR).
  • Hepatitis C virus (HCV) treatment efficacy varies by genotype, with genotype 1 historically showing lower SVR rates, prompting investigations into extended therapy durations.
  • HCV treatment in HIV-coinfected patients involves combined therapy with pegylated interferon and ribavirin, influenced by HIV disease progression and antiretroviral regimens.

Purpose of the Study:

  • To review treatment strategies for difficult-to-treat populations with chronic Hepatitis C virus (HCV) infection.
  • To analyze factors influencing therapeutic efficacy in various HCV genotypes and patient subgroups.
  • To evaluate the effectiveness of re-treatment regimens in patients who did not respond to initial therapies.

Main Methods:

  • Review of multicenter, randomized trials and pharmacokinetic studies on pegylated interferon and ribavirin.
  • Analysis of relationships between patient characteristics (ethnicity, HIV status, renal insufficiency, body mass index, obesity, liver steatosis, insulin resistance) and treatment outcomes.
  • Assessment of re-treatment efficacy in non-responder populations.

Main Results:

  • Patients with HCV genotype 1 showed lower SVR, with longer therapy (72 weeks) suggested.
  • Therapeutic efficacy in genotype 4 HCV was linked to patient ethnicity.
  • Pegylated interferon demonstrated safety and tolerability in renal insufficiency, while ribavirin use remained controversial.
  • Factors like body weight, BMI, obesity, liver steatosis, and insulin resistance were analyzed for their impact on chronic hepatitis C response.
  • Retreatment with pegylated interferon and ribavirin yielded positive results in patients with prior treatment failure.

Conclusions:

  • Optimizing HCV therapy necessitates considering genotype, patient-specific factors, and previous treatment history.
  • Extended treatment durations and re-treatment strategies can improve SVR rates in challenging patient populations.
  • Further research is needed to clarify ribavirin's role in HCV treatment for specific groups, such as HIV-coinfected individuals.

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...